Abivax S.A. Q1 2025 Financials Filed
Ticker: AAVXF · Form: 6-K · Filed: Jun 2, 2025 · CIK: 1956827
| Field | Detail |
|---|---|
| Company | Abivax S.A. (AAVXF) |
| Form Type | 6-K |
| Filed Date | Jun 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-report, quarterly-results, sec-filing
Related Tickers: ABVX
TL;DR
Abivax dropped Q1 2025 financials, showing capital and retained earnings data.
AI Summary
Abivax S.A. filed a 6-K report for the period ending March 31, 2025. The filing includes financial data for the first quarter of 2025, with comparative figures from 2024 and year-end 2023. Key financial statement items like issued capital, share premium, and retained earnings are detailed.
Why It Matters
This filing provides investors with an update on Abivax's financial position and performance for the first quarter of 2025, crucial for assessing the company's ongoing operations and financial health.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing standard financial statement data without significant new disclosures or events.
Key Numbers
- 2025 Q1 — Reporting Period (Financial data pertains to the first quarter of 2025.)
- 2024-03-31 — Comparative Date (Financial data includes comparative figures from March 31, 2024.)
- 2023-12-31 — Year-End Date (Financial data includes comparative figures from year-end 2023.)
Key Players & Entities
- Abivax S.A. (company) — Filer of the report
- 20250331 (date) — Conformed period of report
- 20250602 (date) — Filed as of date
FAQ
What is the reporting period for this 6-K filing?
The conformed period of report is March 31, 2025 (2025 Q1).
When was this 6-K filing submitted to the SEC?
The filing was submitted on June 2, 2025.
What are some of the key financial statement items reported?
The filing details items such as IssuedCapitalMember, SharePremiumMember, ReserveOfExchangeDifferencesOnTranslationMember, and RetainedEarningsProfitLossForReportingPeriodMember.
Are there comparative financial figures included in the report?
Yes, the filing includes comparative data for March 31, 2024, and December 31, 2023.
What is the company's primary industry classification?
Abivax S.A. is classified under Pharmaceutical Preparations [2834].
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 2, 2025 regarding Abivax S.A. (AAVXF).